Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients

Prevalence and clinical significance

Maurizio Vecchi, A. Sinico, M. B. Bianchi, A. Radice, P. Gionchetti, M. Campieri, R. De Franchis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate a) the role of bactericidal/permeability-increasing protein (BPI) as a possible antigen determining perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) reactivity in ulcerative colitis and b) the prevalence and clinical correlates of anti-BPI antibodies in patients with ulcerative colitis on the basis of their p-ANCA status. Methods: p-ANCA and anti-BPI antibodies were evaluated by means of indirect immunofluorescence and enzyme-linked immunosorbent assay methods in a group of 112 ulcerative colitis patients (including 42 patients subjected to proctocolectomy) well defined as far as their clinical features and p-ANCA status. Results: Anti-BPI antibodies were detected in 24% of non-operated patients and were significantly more frequent in p-ANCA-positive patients (32% versus 5% in p-ANCA-negative patients; P <0.015). The prevalence of anti-BPI antibodies was similar in non-operated and operated patients and was high in men, in patients with an extensive and aggressive disease, and in patients developing pouchitis after surgery. Conclusions: These data indicate that BPI is a neutrophil antigen frequently recognized by p-ANCA-positive ulcerative colitis sera. The presence of anti- BPI antibodies appears to identify further immunologic and clinical heterogeneity in ulcerative colitis.

Original languageEnglish
Pages (from-to)1284-1288
Number of pages5
JournalScandinavian Journal of Gastroenterology
Volume33
Issue number12
DOIs
Publication statusPublished - 1998

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Ulcerative Colitis
Serum
Antibodies
Pouchitis
bactericidal permeability increasing protein
Antigens
Indirect Fluorescent Antibody Technique
Neutrophils
Enzyme-Linked Immunosorbent Assay

Keywords

  • Anti-neutrophil cytoplasmic antibodies
  • Autoantibodies
  • Bactericidal/permeability-increasing protein
  • Inflammatory bowel disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients : Prevalence and clinical significance. / Vecchi, Maurizio; Sinico, A.; Bianchi, M. B.; Radice, A.; Gionchetti, P.; Campieri, M.; De Franchis, R.

In: Scandinavian Journal of Gastroenterology, Vol. 33, No. 12, 1998, p. 1284-1288.

Research output: Contribution to journalArticle

@article{654f50b7d3564ac795dccdad672371d4,
title = "Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: Prevalence and clinical significance",
abstract = "Background: The aim of this study was to evaluate a) the role of bactericidal/permeability-increasing protein (BPI) as a possible antigen determining perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) reactivity in ulcerative colitis and b) the prevalence and clinical correlates of anti-BPI antibodies in patients with ulcerative colitis on the basis of their p-ANCA status. Methods: p-ANCA and anti-BPI antibodies were evaluated by means of indirect immunofluorescence and enzyme-linked immunosorbent assay methods in a group of 112 ulcerative colitis patients (including 42 patients subjected to proctocolectomy) well defined as far as their clinical features and p-ANCA status. Results: Anti-BPI antibodies were detected in 24{\%} of non-operated patients and were significantly more frequent in p-ANCA-positive patients (32{\%} versus 5{\%} in p-ANCA-negative patients; P <0.015). The prevalence of anti-BPI antibodies was similar in non-operated and operated patients and was high in men, in patients with an extensive and aggressive disease, and in patients developing pouchitis after surgery. Conclusions: These data indicate that BPI is a neutrophil antigen frequently recognized by p-ANCA-positive ulcerative colitis sera. The presence of anti- BPI antibodies appears to identify further immunologic and clinical heterogeneity in ulcerative colitis.",
keywords = "Anti-neutrophil cytoplasmic antibodies, Autoantibodies, Bactericidal/permeability-increasing protein, Inflammatory bowel disease, Ulcerative colitis",
author = "Maurizio Vecchi and A. Sinico and Bianchi, {M. B.} and A. Radice and P. Gionchetti and M. Campieri and {De Franchis}, R.",
year = "1998",
doi = "10.1080/00365529850172377",
language = "English",
volume = "33",
pages = "1284--1288",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients

T2 - Prevalence and clinical significance

AU - Vecchi, Maurizio

AU - Sinico, A.

AU - Bianchi, M. B.

AU - Radice, A.

AU - Gionchetti, P.

AU - Campieri, M.

AU - De Franchis, R.

PY - 1998

Y1 - 1998

N2 - Background: The aim of this study was to evaluate a) the role of bactericidal/permeability-increasing protein (BPI) as a possible antigen determining perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) reactivity in ulcerative colitis and b) the prevalence and clinical correlates of anti-BPI antibodies in patients with ulcerative colitis on the basis of their p-ANCA status. Methods: p-ANCA and anti-BPI antibodies were evaluated by means of indirect immunofluorescence and enzyme-linked immunosorbent assay methods in a group of 112 ulcerative colitis patients (including 42 patients subjected to proctocolectomy) well defined as far as their clinical features and p-ANCA status. Results: Anti-BPI antibodies were detected in 24% of non-operated patients and were significantly more frequent in p-ANCA-positive patients (32% versus 5% in p-ANCA-negative patients; P <0.015). The prevalence of anti-BPI antibodies was similar in non-operated and operated patients and was high in men, in patients with an extensive and aggressive disease, and in patients developing pouchitis after surgery. Conclusions: These data indicate that BPI is a neutrophil antigen frequently recognized by p-ANCA-positive ulcerative colitis sera. The presence of anti- BPI antibodies appears to identify further immunologic and clinical heterogeneity in ulcerative colitis.

AB - Background: The aim of this study was to evaluate a) the role of bactericidal/permeability-increasing protein (BPI) as a possible antigen determining perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) reactivity in ulcerative colitis and b) the prevalence and clinical correlates of anti-BPI antibodies in patients with ulcerative colitis on the basis of their p-ANCA status. Methods: p-ANCA and anti-BPI antibodies were evaluated by means of indirect immunofluorescence and enzyme-linked immunosorbent assay methods in a group of 112 ulcerative colitis patients (including 42 patients subjected to proctocolectomy) well defined as far as their clinical features and p-ANCA status. Results: Anti-BPI antibodies were detected in 24% of non-operated patients and were significantly more frequent in p-ANCA-positive patients (32% versus 5% in p-ANCA-negative patients; P <0.015). The prevalence of anti-BPI antibodies was similar in non-operated and operated patients and was high in men, in patients with an extensive and aggressive disease, and in patients developing pouchitis after surgery. Conclusions: These data indicate that BPI is a neutrophil antigen frequently recognized by p-ANCA-positive ulcerative colitis sera. The presence of anti- BPI antibodies appears to identify further immunologic and clinical heterogeneity in ulcerative colitis.

KW - Anti-neutrophil cytoplasmic antibodies

KW - Autoantibodies

KW - Bactericidal/permeability-increasing protein

KW - Inflammatory bowel disease

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=0032428570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032428570&partnerID=8YFLogxK

U2 - 10.1080/00365529850172377

DO - 10.1080/00365529850172377

M3 - Article

VL - 33

SP - 1284

EP - 1288

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 12

ER -